Mohr Sector Navigator ETF ENAV 深 沪
已收盘 03-14 16:00:00 美东时间
24.117
0.000
0.00%
华盛通- 最 高--
- 今 开--
- 成交量 0股
- 最 低 --
- 昨 收 24.117
- 总市值 1748.48万
- 52周最高 25.0923
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 22.4723
- 委 比 0.00%
- 总股本 72.50万
- 历史最高 25.0923
- 量 比 0
- 振 幅 0.00%
- 历史最低 22.4723
- 每 手 1
- 风险率 0.00%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Ena S.p.A. Completes Reserved Capital Increase, Alters Shareholding Structure
An update from Enav SpA ( ($IT:ENAV) ) is now available. Ena S.p.A. announced t...
06-28 00:55
Ena S.p.A. Announces New Director Nominations
Enav SpA ( ($IT:ENAV) ) has provided an announcement. Ena S.p.A. announced that...
06-26 01:03
Outlook Therapeutics Secures SMC Approval For LYTENAVA As First And Only Licensed Ophthalmic Bevacizumab For Wet AMD Treatment In UK, Has An Initial 10 Years Of Market Exclusivity From The Date Of Initial Marketing Authorization From The Medicines And Healthcare Products Regulatory Agency
Outlook Therapeutics, Inc. (NASDAQ:OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced the Scottish Medicines Consortium
06-10 20:10
Outlook Therapeutics Launches First-Ever Eye Drug Bevacizumab for Wet AMD in Germany and UK
Outlook Therapeutics, Inc. (NASDAQ:OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced that LYTENAVA™ (bevacizumab
06-02 19:09
Enav S.p.A. Announces Shareholders’ Meeting for 2025
Enav SpA ( ($IT:ENAV) ) has issued an update. Enav S.p.A. has announced the con...
04-18 18:12
Which European equities to buy as UBS upgrades to Overweight?
UBS strategists compiled a list of their high conviction buys within European stocks (VGK), (IEV), (IEUR), (STOXX), (FEZ). In a Thursday note, Andrew Garthwaite, chief global equity strategist at UBS,...
02-14 01:26
Ena S.p.A. Sells Energetika to Refocus on Core Business
Enav SpA ( ($IT:ENAV) ) has shared an announcement. Ena S.p.A. has sold its who...
02-13 04:02
Outlook Therapeutics Vision Loss Drug At Par With Novartis Drug
Outlook Therapeutics plans to resubmit ONS-5010 for FDA approval in 2025 following NORSE EIGHT trial results in wet AMD patients.
01-17 01:09
ENAV S.p.A. Unveils 2025 Financial Calendar and Announces Quarterly Reporting
The latest announcement is out from Enav SpA ( ($IT:ENAV) ). ENAV S.p.A. has re...
01-15 19:22
Top 3 Health Care Stocks That Could Blast Off This Month
The most oversold stocks in the health care sector presents an opportunity to b...
01-06 20:19
